RT Book, Section
A1 Hwang, Andrew Y.
A1 Smith, Steven M.
A1 Gums, John G.
A2 DiPiro, Joseph T.
A2 Talbert, Robert L.
A2 Yee, Gary C.
A2 Matzke, Gary R.
A2 Wells, Barbara G.
A2 Posey, L. Michael
SR Print(0)
ID 1168070951
T1 Adrenal Gland Disorders
T2 Pharmacotherapy: A Pathophysiologic Approach, 10e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9781259587481
LK accesspharmacy.mhmedical.com/content.aspx?aid=1168070951
RD 2024/04/19
AB Content  UpdateDecember  5,  2019Istradefylline:  an  Adenosine  A2A  Receptor  Antagonist  to  Treat  Off  Episodes  in  Parkinson  Disease:  Istradefylline  (Nourianz)  is  the  first  adenosine  A2A  receptor  antagonist  approved  in  the  U.S.  to  treat  off  episodes  in  Parkinson  disease.  Adenosine  A2A  receptors  are  located  in  GABAergic  (γ-aminobutyric  acid)  neurons  within  the  indirect  pathway  of  the  basal  ganglia  system.  Blocking  of  A2A  receptors  (ie,  inhibition  of  the  indirect  pathway)  can  result  in  prolongation  of  dopaminergic  action.  In  randomized,  placebo-controlled  trials,  istradefylline  resulted  in  statistically  significant  reductions  in  daily  off  time.  The  most  common  adverse  reaction  to  istradefylline  is  dyskinesia  followed  by  dizziness,  nausea,  hallucinations,  and  insomnia.  The  recommended  dosage  is  20  mg  orally  once  daily  with  or  without  food.  The  dosage  may  be  increased  to  a  maximum  of  40  mg  once  daily.